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Abstract: 
Aims: To compare disease remission rates, weight loss and changes of metabolic parameters 
of patients after bariatric surgery with non-surgical patients. 
 
Methods: Based on 2006-2017 Hospital Authority database, a population-based retrospective 
cohort of obese type 2 diabetes mellitus (T2DM) patients with and without bariatric surgery 
were identified. Surgical patients were matched with non-surgical patients on 1-to-5 propensity 
score. Remission rates of diabetes, hypertension and dyslipidaemia were reported annually up 
to 60 months. Changes in weight loss measurements (Body Mass Index [BMI], percentage of 
total weight loss [%TWL], percentage of excess weight loss [%EWL], and percentage of 
rebound in excess weight loss [%REWL]) and metabolic parameters (HbA1c, systolic blood 
pressure [SBP], diastolic blood pressure [DBP] and Low-density lipoprotein cholesterol [LDL-
C]) were measured for both groups.  
 
Results: 401 surgical patients (310 restrictive surgeries; 91 bypass surgeries) and 1,894 non-
surgical patients were included. Surgical patients had higher remission rates in diabetes and 
dyslipidaemia, and better glycaemic control at 12-60-month (all p<0.01). SBP and DBP were 
significantly lower for surgical group up to 12-month, and similar between two groups after 
12-month. Surgical patients had significantly lower BMI during follow-up period. %TWL and 
%EWL were higher in the surgery group (15.7% vs. 3.7%; 48.8% vs. 12.0%) at 60-month 
(p<0.001); differences in %REWL between two groups were insignificant. The effectiveness 
of restrictive and bypass surgeries was similar at 60-month, although restrictive surgeries were 
slightly more effective in T2DM remission. 
 
Conclusions: Bariatric surgery was effective in weight loss, remission of diabetes and 
dyslipidaemia in 5-year post-surgery.  
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Bariatric surgery is currently considered as one of the most effective therapies for morbidly 
obese patients (1), since approximately 30% of initial weight of patients is reduced (2, 3) and 
their weight loss is maintained for 10-15 years after the surgery (4). Evidence has also 
suggested that bariatric surgery can ameliorate metabolic syndromes, as well as help patients 
achieve diabetes and other metabolic disorders remission (5-7). Around 75-90% of patients 
who underwent bariatric surgery achieved comorbidity resolution, particularly for patients with 
insulin resistance, hypertension and respiratory disorders (4). Though relapse in recovered 
patients may occur over time, long-term effect of bariatric surgery on disease remission was 
supported by a systematic review, where 66.7% of T2DM patients, 38.2% of hypertensive 
patients, and 60.4% dyslipidaemia patients achieved disease remission at up to 5 years after 
bariatric surgery (8). A prospective cohort study with a follow-up across fifteen years found 
that diabetes remission rates dropped gradually but still exceeded 30% at 15 years after the 
surgery (9).  
 
Bariatric surgery has been recommended as a treatment option of the management of obesity 
and T2DM in several guidelines (10-12) and gained global popularity since last few decades, 
due to its safety and effectiveness in obese patients. The total number of bariatric surgery 
performed worldwide grew rapidly from 146,301 in 2003 to 468,609 in 2013 (13). A similar 
exponential increase in bariatric surgery performed was also found in Asia Pacific countries, 
whereby the number almost doubled during the period of 2011-2013 and reached to 46,110 in 
2013 (13). In the past few years, many studies affirmed the efficacy of bariatric surgery on 
weight reduction, disease remission, and changes of disease-related clinical parameters among 
Chinese and other Asian populations (14-21). However, most of these studies either had a 
limited follow-up period up to 24 months (14, 17-20), or recruited relatively small number of 
patients from a single centre (15, 16).  
 
Whether types of surgery affect the effectiveness of bariatric surgery in T2DM remission and 
weight reduction has become a hot research topic. All current evidences indicate that 
laparoscopic sleeve gastrectomy (LSG) and other bariatric surgical procedures, including 
 
laparoscopic gastric bypass (LGB) and laparoscopic adjustable gastric banding (LAGB), are 
all well-tolerated and efficacious procedures for obese patients with T2DM (22-25). However, 
the answer to if one surgical procedure is superior to another is uncertain and still under further 
investigation.   
 
Therefore, a long-term population-based study using real-world data to estimate the 
effectiveness of bariatric surgery and to compare different surgical procedures should be 
conducted. This study aimed 1) to evaluate the effect of bariatric surgery on multiple disease 
remissions on obese patients with T2DM, 2) to illustrate the changes of metabolic parameters 
over five years by using population-based data, and 3) to compare the effectiveness between 
restrictive and bypass surgeries. 
 
Materials and Methods 
Study Design and Patient Sampling 
This study was a population-based retrospective propensity score-matched cohort study. 
Patients with T2DM undergoing bariatric surgery between 1 January 2006 and 31 December 
2017 were retrieved from Hospital Authority Clinical Management System (HA/CMS) by 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
procedure Codes. T2DM was identified by ICD-9-CM diagnosis codes and International 
Classification of Primary Care (ICPC-2) diagnosis codes (Supplemental Table 1). HA is a 
statutory body that is accountable to Hong Kong government. Indeed, HA/CMS contains valid 
and substantial clinical data, which have been largely used in population-based studies (26, 27). 
Patients with type 1 diabetes or gestational diabetes were excluded from this study. In line with 
International Federation for the Surgery of Obesity and Metabolic Disorders-Asia Pacific 
Chapter (IFSO-APC) (28) and international guideline and consensus (29), the BMI threshold 
of 27.5 kg/m2 was one of the surgery indications for Asian patients. Hence, patients with a BMI 
reading ≥27.5 kg/m2 on the index date were included. A control group of obese patients (BMI 
≥30 kg/m2, defined by World Health Organisation [WHO] (30)) who have ever utilised 
healthcare services and have not ever underwent bariatric surgery during the above observation 
period was selected for comparison. The index date for surgical patients was set as the date of 
bariatric surgery. The index date for patients in the control group was the date of bariatric 
 
surgery of their matched surgical patients. The follow-up period was from the index date to up 
to 60 months after the index date. 
 
Outcomes 
Primary outcomes were prevalent remission rates, attrition-adjusted remission rates, 
cumulative remission rates and attrition-adjusted remission rates (31) of diabetes, hypertension, 
dyslipidaemia, high Low-density Lipoprotein Cholesterol (LDL-C), low High-density 
lipoprotein Cholesterol (HDL-C), and high triglycerides of both surgical and non-surgical 
patients up to 60 months after the index date.  
 
Secondary outcomes were the changes of metabolic parameters, including BMI, Haemoglobin 
A1c (HbA1c), systolic blood pressure (SBP), diastolic blood pressure (DBP), and LDL-C, as 
well as weight loss measurements, including percentage of total weight loss (%TWL), excess 
weight loss (%EWL), and percentage of rebound in excess weight loss (%REWL). As HbA1c 
<7.0% is one of glycaemic goals for adults (32), percentage of patients who achieved this target 
was also included as one of secondary outcomes. The measurement points of secondary 




Complete diabetes remission was defined as normoglycaemia with HbA1c <6.0% and fasting 
glucose <5.6 mmol/L for at least 1 year without any anti-diabetic pharmacologic therapy or 
ongoing bariatric surgical procedures (33). Partial diabetes remission was defined as HbA1c of 
6.0%-6.5% and fasting glucose of 5.6-6.9 mmol/L for at least 1 year without any anti-diabetic 
pharmacologic therapy or ongoing bariatric surgical procedures (33). Remission of 
hypertension was defined as an SBP <140 mmHg and a DBP <90 mmHg for at least 1 year 
without anti-hypertensive pharmacologic therapy (34). Remission of dyslipidaemia was 
defined as LDL-C <4.14 mmol/L, HDL-C ≥1.03 mmol/L, and triglycerides <2.26 mmol/L 
without taking any lipid-lowering medication for at least 1 year. Based on the recent American 
Association of Clinical Endocrinologists and American College of Endocrinology 
 
(AACE/ACE) dyslipidaemia guideline (35), remission of high LDL-C, low HDL-C and high 
triglycerides was defined as LDL-C <2.59 mmol/L (for moderately risk people), HDL-C >1.03 
mmol/L, and triglycerides <2.26 mmol/L for at least 1 year without any lipid-lowering 
medications, respectively. 
 
For patients who initially experienced disease remission after the index date, relapse of 
different diseases was defined as follows. Relapse of diabetes was defined as restarting diabetes 
medications, HbA1c >6.5%, or fasting glucose ≥6.9 mmol/L. Relapse of hypertension was 
defined as SBP ≥140 mmHg, DBP ≥90 mmHg, or retaking any anti-hypertensive drugs. 
Relapse of dyslipidaemia was defined as LDL-C ≥4.14 mmol/L, HDL-C <1.03 mmol/L, 
triglycerides ≥2.26 mmol/L, or taking a lipid-lowering medication. Relapse of high LDL-C (for 
moderately risk people) was defined as either restarting lipid-lowering medications or LDL-C 
≥2.59 mmol/L. Relapse of low HDL-C was defined as either restarting lipid-lowering 
medications or HDL-C ≤1.03 mmol/L. Similarly, relapse of high triglycerides was defined as 
either restarting lipid-lowering medications or triglycerides ≥2.26 mmol/L. 
 
Prevalent remission rate was calculated as dividing the number of patients who were in 
remission at the time of measurement by the number of patients retained, whereas cumulative 
remission rates were ratios of number of patients who have ever achieved remission and the 
number of patients retained. For attrition-adjusted remission rates, extreme-case imputation 
was adopted, i.e. patients who lost to follow-up were considered as no remission (31). 
Therefore, attrition-adjusted prevalent remission was calculated as dividing the number of 
patients who were in remission at the time of measurement by the number of patients with the 
certain disease at the index date, while  attrition-adjusted cumulative remission rates were ratios 
of number of patients who have ever achieved remission and initial number of patients with 
the certain disease at the index date (31).  
 
%TWL was defined as the ratio of weight difference between baseline and postsurgical follow-
ups to the baseline weight. %EWL was calculated as weight difference between baseline and 
follow-ups divided by the difference between baseline and ideal weight. Ideal weight equalled 
to the ideal BMI (25 kg/m2) (16) multiplied by square of height in meters. %REWL was the 
 
percentage difference between the %EWL measured and the best %EWL achieved during the 
follow-up period (16).  
 
Propensity Score Matching 
To address the absence of baseline data, multiple imputation by chained equations (MICE) (36) 
was used for both surgical and control patients. The number of imputations was 20. HbA1c, 
SBP, DBP and LDL-C were imputed by other clinical parameters such as BMI, gender, age, 
total cholesterol, HDL-C, serum creatinine, triglyceride fasting glucose, Charlson Comorbidity 
Index, use of oral anti-diabetic drugs, use of insulin, use of anti-hypertensive drugs, use of lipid 
lowering agents, and history of mental health problems, hyperlipidaemia, obstructive sleep 
apnoea, gallbladder disease, musculoskeletal and chronic orthopaedic disorders, and 
hypertension. Model parameters were estimated from multiply imputed data and then used to 
obtain multiple-imputation linear predictions by applying Rubin’s combination rules 
observation wise to the completed-data predictions (37). Propensity Score Matching was 
performed using the predictions obtained after MICE. 
 
The propensity scores of all enrolled patients were calculated by using multivariable logistic 
regression adjusting for baseline covariates. Those covariates included age, gender, BMI, 
HbA1c, SBP, DBP, total cholesterol, HDL-C, LDL-C, serum creatinine, triglyceride, fasting 
glucose, Charlson Comorbidity Index, use of oral anti-diabetic drugs, use of insulin, and history 
of hypertension, mental health problems, hyperlipidaemia, obstructive sleep apnoea, 
gallbladder disease, musculoskeletal and chronic orthopaedic disorders. The caliper criteria 
improved the quality of the nearest neighbour matching by specifying a maximum tolerance of 
the propensity score distance between patients in the surgical group and in the control group. 
The propensity score matching was performed by ‘calipmatch’ command on one-to-five basis 
without replacement in STATA. 
 
Statistical Analysis 
Baseline socio-demographic and clinical characteristics of study population were presented by 
frequency with percentages for categorical variables and means with standard deviation (SD) 
 
for continuous variables. Independent t-tests and chi-square tests were used to assess the 
differences between the surgery and control group for categorical variables and continuous 
variables, respectively. Covariates balance between the two groups after matching was 
indicated by standardised mean difference, when the standardised mean differences of baseline 
covariates were less than 0.1. 
 
Primary and secondary outcomes at baseline and at follow-ups were displayed in mean values 
with 95% confidence interval (CI). Logistic regression models or independent t-tests were used 
to detect the differences of all these measurements in each follow-up point between two groups 
and two surgical procedures. 
 
All statistical analyses were performed using the STATA version 13.0 (StataCorp LP, College 
Station, TX, USA). All significance tests were two-tailed and p-value smaller than 0.05 was 




Supplemental Figure 1 visualises the study flow. A total of 668 patients with relevant ICD-
9-CM procedure codes were identified. After excluding patients who had index date in the year 
of 2018, were non-T2DM, had missing BMI, had non-bariatric procedural operation or had 
BMI <27.5 kg/m2 on the index date, 422 patients were included. For patients without bariatric 
surgery, a total of 288,017 patients were initially identified, and 42,307 eligible patients 
remained. After 1-to-5 propensity score matching, 401 obese patients in the surgery group were 
successfully matched with 1,894 obese patients in the control group. Patients were observed 
for up to 60 months. There were 86 surgical and 394 control patients available for analysis at 
the end of follow-up. The median follow-up period for 422 surgical patients before matching, 
401 patients in the surgery group and 1,894 patients in the control group is 23 months, 23 
months and 33 months, respectively.  
 
 
Baseline characteristics of study population before and after propensity score matching were 
summarised in Table 1. For 422 eligible surgical patients before matching, 327 (77.5%) 
underwent restrictive surgeries (315 LSG; 12 LAGB) and 95 (22.5%) underwent bypass 
surgeries (18 laparoscopic sleeve gastrectomy with duodenojejunal bypass (LSG/DJB); 77 
LGB). 1-to-5 propensity score matching method well balanced the socio-demographic 
background, clinical parameters and comorbidities of surgical and non-surgical patients. The 
mean BMI of surgical patients and non-surgical patients were 36.81 kg/m2 and 36.31 kg/m2 
(p=0.121), respectively; and the T2DM duration of two groups were 4.12 years and 4.36 years 
(p=0.136). For 401 obese T2DM patients in the surgery group, 91 (22.7%) patients underwent 
bypass procedures (17 LSG/DJB; 74 LGB), and 310 (77.3%) patients underwent restrictive 
procedures (299 LSG; 11 LAGB).  
 
Prevalent remission rates 
The diabetes complete remission rates of patients in the bariatric surgery group were 
significantly higher than those of patients in the control group during the whole follow-up years. 
The T2DM complete remission rates of surgical patients peaked at 24 months (26.4%) and 
fluctuated between 16.7% and 20.6% in the remaining years, whereas no more than 3.5% of 
patients in the matched control group were free from T2DM over 5 years. (Figure 1a) Prevalent 
diabetes complete or partial remission rates of surgical patients increased from 5.0% in 12 
months to 28.3% in 24 months and dropped to 22.1% in 60 months; while those of non-surgical 
patients fluctuated slightly around 5.0% over 60 months. Surgical patients had higher complete 
or partial diabetes remission rates at and after 24 months (p<0.001). (Figure 1b) 
 
The prevalent hypertension remission rates of both groups did not exceed 6.5% during the 
follow-up period, and bariatric surgery did not show superiority in resolving hypertension 
when compared with no surgery (p-value ranged from 0.119 to 0.540). (Figure 1c) 
Significantly larger percentage of patients in the surgery group than patients in the matched 
control group achieved significantly high LDL-C, low HDL-C and high triglycerides remission 
across 5 years. (Supplemental Figure 3a, 4a, 5a) Bariatric surgery also showed a compelling 
advantage in resolving dyslipidaemia, as prevalent remission rates of dyslipidaemia of surgical 
patients were higher than those of non-surgical patients at all measurement points (p<0.001). 
(Figure 1d)  
 
 
Attrition-adjusted prevalent remission rates 
After adjustment of attrition, prevalent complete diabetes remission rates of surgical patients 
were still significantly higher than those of non-surgical patients from 12 months to 60 months. 
(Figure 1e) The patterns of attrition-adjusted prevalent diabetes complete or partial remission 
rates were similar to those of prevalent diabetes complete or partial remission rates. (Figure 
1f) Also, hypertension remission between two groups were not significantly different all the 
time. (Figure 1g) Similar to prevalent remission rates, attrition-adjusted prevalent remission 
rates of high LDL-C, low HDL-C, high triglycerides and dyslipidaemia of surgical patients 
were significantly higher than those of the control group at all measurement points. (Figure 
1h; Supplemental Figure 3b, 4b, 5b) 
 
Cumulative remission rates 
Figure 2a-d and Supplemental Figure 3c, 4c and 5c describe the cumulative disease 
remission rates of both groups. The five-year cumulative diabetes complete remission rates, 
diabetes complete or partial remission rates, high LDL-C remission rats, low HDL-C remission 
rates, high triglycerides remission rates and dyslipidaemia remission rates of surgical patients 
were 25.6%, 32.6%, 24.3%, 41.7%, 38.2%, and 40.3%, respectively. All above rates were 
significantly higher than those of non-surgical patients. However, five-year cumulative rates 
of hypertension remission did not differ between two groups. 
 
Attrition-adjusted cumulative remission rates 
Similar to the above cumulative remission rates, patients in the surgery group had greater 
attrition-adjusted cumulative rates in diabetes complete remission, diabetes complete or partial 
remission, high LDL-C remission, low HDL-C remission, high triglycerides remission, and 
dyslipidaemia remission over time. Apart from 12 months, when the control group had higher 
attrition-adjusted cumulative hypertension remission rate (p=0.037), no other significant 
differences were found in this outcome from 24 to 60 months. (Figure 2e-h; Supplemental 
Figure 3d, 4d, 5d). 
 
 
Change of metabolic parameters 
The effect of bariatric surgery on HbA1c reduction was significant, as the mean HbA1c of 
patients in the surgery group dropped rapidly from 7.66% at baseline to 6.30% at 6 months, 
and ended up at 6.93% at 60 months. The mean HbA1c of surgical patients at each follow-up 
point was significantly lower than that of their counterparts. Significantly more percentage of 
T2DM patients in the surgery group achieved the target of HbA1c <7% than patients in the 
control group across 5 years. At 5 year after surgery, the percentage of surgical patients and 
non-surgical patients achieved this target were 60.0% and 44.3%, respectively (p=0.014). 
Bariatric surgery lowered both SBP and DBP within 12 months, however, the effect did not 
persist in the remaining years. Non-surgical patients had significantly lower LDL-C level than 
surgical patients at 6, 36 and 48 months, indicating that bariatric surgery did not show much 
effect on lowering LDL-C. (Figure 3a-e) 
 
Change of weight Loss measurements  
The mean BMI of patients in the surgery group dropped from 36.81 kg/m2 at baseline to 32.21 
kg/m2 at 60 months. Although patients in the matched control group also experienced BMI 
reduction during the follow-up period, their mean BMI was significantly higher than surgical 
patients on each time point. Furthermore, we gained similar findings for the parameters 
of %TWL and %EWL. Patients in the surgery group lost 15.7% of the initial weight, while 
patients in the control group only lost 3.7% of initial weight within 60 months (p<0.001). The 
highest %EWL for patients in the surgery group equalled 69.6% at 12 months and fluctuated 
to 48.8% at the end of follow-up. The %EWL of non-surgical patients increased slowly, but 
were significantly lower than that of surgical patients over time (p<0.001). Generally, %REWL 
between patients in two groups were not significantly different, except at 3 and 12 months 
(p<0.001). (Figure 3f-i) 
 
Comparison between restrictive and bypass surgeries 
Supplemental Figure 6-8 display the disease remission rates and changes of metabolic and 
weight parameters for surgical patients over time. Overall, the effectiveness of restrictive and 
bypass surgeries were similar. No significant difference was found in remission rates of 
hypertension and dyslipidaemia between two different surgical procedures. Of note, patients 
 
underwent restrictive surgeries had significantly higher attrition-adjusted prevalent and 
cumulative diabetes remission rates from 24 months onwards. However, patients underwent 
bypass surgeries had significantly lower LDL-C level until 36 months. Also, bypass surgeries 
showed better effectiveness in weight reduction within 12 months after surgery. However, it 
was probably due to the fact that bypass patients had lower baseline BMI than restrictive 
patients (34.72 kg/m2 vs 37.84 kg/m2, p<0.001).  
 
Discussion 
To best of our knowledge, the present study is the largest cohort study that evaluated the 
effectiveness of bariatric surgery among Chinese population using population-based data (15-
17, 38-40). Also, this study made a comprehensive illustration of metabolic and weight 
outcomes, including complete and partial remission rates of diabetes, remission rates of 
hypertension, high LDL-C, low HDL-C, high triglycerides and dyslipidaemia, and 
improvement of BMI, HbA1c, SBP, DBP, LDL-C, %TWL, %EWL, and %REWL. The 
definition of disease remission after bariatric surgery varied greatly from one study to another 
(16, 41-44), impeding direct comparisons among studies. In this study, T2DM, hypertension 
and dyslipidaemia remission were defined based on the most updated guidelines published by 
American Diabetes Association, European Society Cardiology and the European Society of 
Hypertension and AACE/ACE, respectively (33-35), since these guidelines are widely 
accepted. As suggested by Isaman et al (31), results of existing studies that evaluated 
effectiveness of bariatric surgery on disease remission varied widely, hence additional 
reporting on both attrition-adjusted cumulative and prevalent remission rates after bariatric 
surgery could support in decision making process and making comparison across studies. In 
the present study, prevalent remission rates, attrition-adjusted prevalent remission rates, 
cumulative remission rates, and attrition-adjusted cumulative remission rates were all 
measured in both surgical and matched control groups. Also, we compared the effectiveness of 
two different types of surgery, the results of which could help bariatric surgeons in choosing a 
suitable surgery for patients. Combined with above strengths, our findings can reflect the 
effectiveness of bariatric surgery among obese patients with T2DM and support fair 
comparison of remission rates among studies. 
 
 
The results of this study were in line with the conclusion of previous observational studies and 
randomised controlled trials (RCTs), which found that bariatric surgery provided substantial 
and sustainable effects on weight loss, glycaemic control and lipid profile improvement (15, 
42, 44-46). However, observations of the present study were at variance with other studies 
regarding to diabetes remission and weight loss in quantitative aspect and hypertension 
remission from qualitative perspective.  
 
Though the effects of bariatric surgery on T2DM was confirmed in this study, our results of 
prevalent complete diabetes remission rates were relatively low when compared with studies 
focused on either Caucasians or Chinese populations (16, 39, 44, 47). For instance, Swedish 
Obese Subjects (SOS) study, one of the largest and longest prospective study, found that T2DM 
recovery rates of Swedish patients with bariatric surgery were 72% at 2 years (47); but only 
26.4% of surgical patients at 24 months were found to achieve diabetes remission in our study. 
The quantitative differences in diabetes recovery rates among studies may due to the 
heterogeneity of remission definition. Actually, many existing studies that discussed the 
effectiveness of bariatric surgery on T2DM had largely varied T2DM remission criteria, 
leading to direct comparisons across studies difficult and inappropriate. However, another 
single-centre observational study in Hong Kong (16), which adopted the same stringent 
definition of diabetes remission as we did to evaluate the 5-year T2DM remission rates among 
65 Chinese patients with LSG, still reported relatively higher T2DM remission rates than us. 
Apart from sample size, baseline duration of T2DM, fasting glycaemia, HbA1c and waist 
circumference of included patients were all essential determinants that led to the differences of 
T2DM remission rates between studies (48). 
 
This study confirmed that surgical patients experienced more improvements of lipid profile, as 
remission rates of hyperlipidaemia, low HDL-C, high LDL-C and hypertriglyceridemia of 
surgical patients were significant higher than their non-surgical peers. However, unlike the 
results reported by Jamal et al (42), mean LDL-C level of surgical patients in the current study 
did not dropped greatly over the years and was not significantly lower than those of non-
surgical peers. This was because the baseline LDL-C of our surgical cohort was only 2.39 
mmol/L, which was lower than the cut-off of high LDL-C (≥2.59mmol/L). In the contrast, the 
 
baseline LDL-C of patients in the mentioned cohort study (42) was 3.50 mmol/L (135 mg/dL), 
and thus those patients had more room in LDL-C reduction.  
 
Our study did not support that bariatric surgery was associated with hypertension remission. 
Reported hypertension remission rate of an observational cohort study was 38.2% among LGB 
participates at year 3 post surgery (46), while the prevalent hypertension remission rates in our 
study did not exceed 6.5% over the years. One possible explanation of the relatively low 
hypertension remission rates in our study was that a stringent criterion of hypertension 
remission was adopted in our study; whereas the definition of hypertension remission of the 
mentioned cohort study (46) did not require patients to stay hypertension-free for at least one 
year.   
 
Occurrence of weight regain after bariatric surgery was acknowledged in several studies (49, 
50), as well as in the current study. Change patterns of both BMI and %TWL in our study 
verified the weight rebound in Hong Kong patients with bariatric surgery. However, though 
there was weigh rebound, reported %TWL and %EWL in a US cohort (50) and a meta-analysis 
(5) was around 30% and 60%, respectively, within 5 years. Compared with those studies, 
both %TWL and %EWL of the present study were relatively low, possibly resulting from 
difference of ethics origin. Actually, both %EWL and %REWL of the present study were close 
to the ones reported by the local study (16). Notably, patients in the control group also 
experienced weight loss over the years and around 5% of control patients achieved T2DM 
remission, although their %TWL did not exceed 5% as stated in the previous literature review 
(49). This may because most of diabetic patients in Hong Kong were enrolled in the Risk 
Assessment and Management Program (RAMP-DM), which is a territory-wide program 
launched by HA in 2008 (26). This program, assessed individual risk level and managed 
patients by multidisciplinary teams, reduced the HbA1c and BMI within 5-year follow-up (26). 
 
Several limitations of the present study should be acknowledged. Firstly, the inclusion criteria 
of BMI for patients in the surgery and the control groups was slightly different. For surgical 
patients, we used guideline-recommended BMI cut-off for Asian patients who should consider 
bariatric surgery (28), while we adopted WHO’s definition of obesity (30) for the control group. 
 
Despite of the discrepancy, the baseline BMI of both groups were well balanced. Secondly, 
over half of enrolled surgical patients underwent bariatric surgery after the year of 2013, and 
they did not achieve 5-year follow-up. Besides, due to the nature of observational database 
study, clinical parameters were routinely measured for those complying with healthcare follow-
up appointments, and not available for those who defaulted or re-scheduled the appointments. 
Hence, the results of this study, especially those of 48-60 months, may be biased. Our 
comparative results between restrictive and bypass surgeries indicated that restrictive surgeries 
were slightly more preferred for T2DM patients, while bypass surgeries were more effective 
in LDL-C and weight reduction in first few months after surgery. However, as less than 50% 
of initial study population were available for analysis at the end of follow-up, surgeons should 
be cautious when using these results, especially those of later years. In addition, we limited the 
follow-up period in this study to 60 months. Ideally, an extensive follow-up period would allow 
robust data analyses and generate more reliable results. For example, the follow-up duration of 
the SOS trial (51) was 12-25 years and that of SurgiCal Obesity Treatment Study (SCOTS) 
(52) will be 10 years or beyond. However, though bariatric surgery had a history of over 60 
years, it was firstly introduced to Hong Kong in the early 2000s and only started rising only in 
recent few years (20). Therefore, studies with larger sample size and longer follow-up duration 
should be conducted in the future. Lastly, like most comparative studies (6, 18, 40), this study 
compared the patients with bariatric surgery with those under usual care. However, comparison 
of effectiveness between bariatric surgery and conventional therapies, such as lifestyle 
interventions and medications, is not proper to some extent. This is not only because 
hypotheses that bariatric surgery is superior to usual care in metabolic parameter improvement 
and disease remission have been widely confirmed by numerous previous studies (5), but also 
due to the fact that surgical patients are mainly those who failed first-line therapies (10) and 
are supposed to be less healthy than non-surgical patients. Besides, though this propensity 
score-matched study using real-word data reflect the actual clinical aspects, RCTs are actually 
given the highest level of evidence since they are less biased and have less risk of systematic 
errors (53). Therefore, a more appropriate design of RCT for the measurement of effectiveness 
of bariatric surgery versus other relevant therapies still needs further discussion.  
 
In conclusion, among obese T2DM patients, bariatric surgery was associated with increased 
remission of diabetes and hyperlipidaemia, and reduction in body weight, BMI, HbA1c and 
LDL-C in 5-year post-surgery. The effectiveness of restrictive and bypass surgeries was similar 
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Figure 1: Prevalent remission rates of patients in the surgery and control group, a) diabetes 
complete; b) diabetes complete or partial; c) hypertension; d) dyslipidaemia; e) Attrition-
adjusted prevalent diabetes complete; f) Attrition-adjusted prevalent diabetes partial; g) 
Attrition-adjusted prevalent hypertension; and h) Attrition-adjusted prevalent dyslipidaemia  
Figure 2: Cumulative remission rates of patients in the surgery and control group, a) diabetes 
complete; b) diabetes complete or partial; c) hypertension; d) dyslipidaemia; e) Attrition-
adjusted prevalent diabetes complete; f) Attrition-adjusted prevalent diabetes partial; g) 
Attrition-adjusted prevalent hypertension; and h) Attrition-adjusted prevalent dyslipidaemia  
Figure 3: Changes in weight loss and metabolic outcomes in the surgery and control group, a) 
HbA1c, b) HbA1c<7%, c) systolic blood pressure, d) diastolic blood pressure, e) low-density 
lipoprotein cholesterol, f) body mass index, g) percentage of total weight loss, h) percentage of 
excess weight loss; and i) percentage of rebound in excess weight loss 
 
Table 1 Baseline characteristics of patients in the bariatric surgery and matched control group 
 Before matching After 1-to-5 propensity score matching 
Characteristics Bariatric surgery patients (n = 422) 
Bariatric surgery patients 
(n = 401) 
Matched control patients 
(n = 1894) p-value SMD
¶ 
Socio-demographic      
Female, n (%) 210 (49.8) 201 (50.1) 966 (47.6) 0.353 0.051 
Mean age (SD), year 53.21 (13.39) 53.36 (13.29) 53.28 (13.70) 0.916 0.006 
Clinical parameters      
Mean BMI (SD), kg/m2 37.14 (5.42) 36.81 (5.09) 36.31 (6.13) 0.121 0.090 
Mean weight (SD), kg 100.53 (18.94) 99.62 (18.09) 93.90 (18.51) <0.001* 0.313 
Mean height (SD), m 1.64 (0.09) 1.64 (0.09) 1.61 (0.11) <0.001* 0.345 
Mean waist circumference, cm 113.60 (12.33) 113.17 (12.03) 109.73 (12.72) <0.001* 0.278 
Mean HbA1c, % 7.65 (1.54) 7.66 (1.51) 7.56 (1.77) 0.262 0.065 
Mean SBP (SD), mmHg 134.30 (16.89) 134.66 (16.76) 134.00 (16.69) 0.520 0.040 
Mean DBP (SD), mmHg 77.26 (10.33) 77.50 (10.37) 77.35 (10.32) 0.809 0.015 
Mean total cholesterol (SD), mmol/L 4.32 (0.93) 4.31 (0.93) 4.27 (0.92) 0.362 0.050 
Mean HDL-C (SD), mmol/L 1.08 (0.30) 1.09 (0.29) 1.08 (0.27) 0.536 0.033 
Mean TC/HDL-C ratio (SD) 4.24 (1.53) 4.20 (1.31) 4.14 (1.18) 0.364 0.049 
Mean LDL-C (SD), mmol/L 2.40 (0.81) 2.39 (0.80) 2.35 (0.75) 0.297 0.057 
Mean triglyceride (SD), mmol/L 1.93 (1.48) 1.88 (1.21) 1.90 (1.33) 0.842 0.011 
Mean fasting glucose (SD), mmol/L 7.96 (2.86) 8.01 (2.86) 7.80 (2.78) 0.181 0.074 
Mean serum creatinine (SD), umol/l 83.51 (66.05) 84.31 (67.59) 83.96 (54.63) 0.910 0.006 
Mean eGFR (SD), ml/min/1.73m2 93.02 (30.95) 92.35 (31.03) 90.82 (30.14) 0.359 0.050 
Mean duration of DM (SD), year 4.02 (3.14) 4.12 (3.14) 4.36 (2.84) 0.136 0.079 
    Insulin used, n (%) 83 (19.7) 78 (19.5) 362 (19.1) 0.876 0.009 
    Oral anti-diabetic drugs ever used, n (%) 235 (55.7) 231 (57.6) 1127 (59.5) 0.495 0.037 
Comorbidities      
History of hypertension, n (%) 334 (79.2) 319 (79.6) 1464 (77.3) 0.336 0.054 
    Anti-hypertensive drugs ever used, n (%) 326 (77.3) 313 (78.1) 1470 (77.6) 0.829 0.012 
History of hyperlipidaemia, n (%) 218 (51.7) 205 (51.1) 960 (50.7) 0.874 0.009 
    Lipid lowering agents ever used, n (%) 225 (53.3) 214 (53.4) 1059 (55.9) 0.351 0.051 
History of mental health problems, n (%) 22 (5.2) 21 (5.2) 112 (5.9) 0.598 0.029 
History of obstructive sleep apnoea, n (%) 235 (55.7) 220 (54.9) 1040 (54.9) 0.986 0.001 
History of gall bladder disease, n (%) 36 (8.5) 34 (8.5) 140 (7.4) 0.455 0.040 
History of musculoskeletal and chronic orthopaedic 
disorders, n (%) 103 (24.4) 98 (24.4) 481 (25.4) 0.689 0.022 
Mean Charlson comorbidity index (SD) 3.68 (1.92) 3.70 (1.95) 3.58 (1.90) 0.226 0.066 
Notes: 
Abbreviations: SMD = Standardised Mean Difference; SD = Standard Deviation; BMI = Body Mass Index; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; HDL-C = High-
density Lipoprotein Cholesterol; TC = Total Cholesterol; LDL-C = Low-density Lipoprotein Cholesterol; eGFR = estimated glomerular filtration rate; DM = Diabetes Mellitus 
*Significant difference (p-value <0.05) detected by independent t tests or by chi square tests.  
¶ SMD <0.100 indicates the balance of baseline covariates. 
 
 



